title: Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes.
abstract: BACKGROUND
  Cardiovascular disease is a major cause of mortality in type 1 diabetes (TIDM). TIDM is a proinflammatory state. Whereas there is consensus on lipid management in type 2 diabetes, there is a lack of data in type 1 diabetes. In addition to benefits on the lipid profile, statin therapy is antiinflammatory.
  
  
  OBJECTIVE
  There are scant data on statin therapy in T1DM. Thus, we tested the effect of simvastatin, compared with placebo, on biomarkers of inflammation and monocyte function in TIDM patients.
  
  
  METHODS
  This was a double-blind, randomized, placebo-controlled study of T1DM patients, randomized to placebo or simvastatin, 20 mg/d for 3 months.
  
  
  METHODS
  The study was conducted at the University of California, Davis, Medical Center.
  
  
  METHODS
  Participants included patients with T1DM.
  
  
  RESULTS
  Analytes measured at baseline and 3 months included liver function tests, creatinine, hemoglobin AIC, high-sensitivity C-reactive protein, soluble CD40 ligand, monocyte O(2)(-), cytokines, nuclear factor-kappaB. Simvastatin therapy resulted in significant reduction in low-density lipoprotein and non-high-density lipoprotein cholesterol, high-sensitivity C-reactive protein (18% reduction, P < 0.001) and soluble CD40 ligand (22% reduction, P < 0.05), compared with placebo. Simvastatin therapy significantly inhibited lipopolysaccharide-activated monocyte release of O(2)(-) (P < 0.0005), IL-8 (P < 0.03), and TNF (P < 0.02). Simvastatin therapy significantly inhibited monocyte IL-6 release, compared with baseline (P = 0.02). Simvastatin therapy also significantly reduced monocytic nuclear factor-kappaB p65 activity, compared with placebo (P < 0.01).
  
  
  CONCLUSIONS
  This study demonstrates that simvastatin (20 mg/d) is safe in T1DM patients and has concomitant benefits on the lipid profile and biomarkers of inflammation. These novel findings could have implications for developing policy guidelines for statin therapy in forestalling vascular complications in young T1DM.
authors.affiliation: Laboratory for Atherosclerosis and Metabolic Research, University of California, Davis, Medical Center, Sacramento, California 95817, USA. ishwarlal.jialal@ucdmc.ucdavis.edu
authors.forename: Ishwarlal
authors.initials: I
authors.lastname: Jialal
authors.forename: Eric
authors.initials: E
authors.lastname: Miguelino
authors.forename: Steven C
authors.initials: SC
authors.lastname: Griffen
authors.forename: Sridevi
authors.initials: S
authors.lastname: Devaraj
mesh_terms: D000328:Adult; D015415:Biomarkers; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood*; D016207:Cytokines / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007249:Inflammation / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D009000:Monocytes / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D019821:Simvastatin / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D015415:Biomarkers; D002784:Cholesterol; D008078:Cholesterol, LDL; D016207:Cytokines; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; D019821:Simvastatin; D014280:Triglycerides